All patients with symptoms of COVID-19, recent at-risk travel, or contact with a person confirmed or awaiting testing for COVID-19 are being asked to reschedule their appointment. Critical appointments will be considered on a case-by-case basis.
Please see our COVID-19 screening questionnaire to see if the above policy applies to your upcoming appointment.
This policy also applies to anyone planning to accompany patients to their appointment.
Patients older than 65, especially those with other significant health problems such as diabetes or congestive heart failure are strongly advised to avoid in-office appointments at least through the end of March.
We are actively working to implement a teledermatology system in order to continue to serve the needs of our patients while also protecting patients and staff from infection. Detailed information about this coming option is available on our teledermatology page and will be updated as information becomes available.
to read more about teledermatology, please click here.
Biologics include Humira, Enbrel, Cosentyx, Taltz, Ilumya, Tremfya, Skyrizi, Stelara, Siliq
For patients on biologic therapy please refer to this link to learn about the Academy of Dermatology’s COVID-19 outbreak statement.